WASHINGTON, Dec. 7 /PRNewswire/ -- Jim Greenwood, President and CEO of
the Biotechnology Industry Organization (BIO), issued the following
statement on the Senate's confirmation of Andrew von Eschenbach, M.D., as
Commissioner of the Food and Drug Administration (FDA):
"BIO applauds Majority Leader Bill Frist and Members of the U.S. Senate
for moving forward to confirm Dr. Andrew von Eschenbach. He has served the
nation well as the Acting Commissioner of the FDA. This confirmation will
enable him to provide effective leadership and vision for the FDA and is a
critical step toward strengthening the FDA.
"Dr. von Eschenbach's experience as a urologic surgeon and oncologist
and his leadership as director of the National Cancer Institute afford him
unique insights into the critical need to advance new treatments for
patients with life-threatening illnesses. As a teacher and academician, he
appreciates the importance of education and research in achieving
scientific breakthroughs.
"BIO staff and member companies look forward to continuing our work
with Dr. von Eschenbach to provide safe, effective and innovative products
into the hands of patients and other consumers while assuring public
confidence in these products."
BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations across
the United States and 31 other nations. BIO members are involved in the
research and development of healthcare, agricultural, industrial and
environmental biotechnology products. http://www.bio.org
Upcoming Events
* BIO CEO & Investor Conference
Feb. 12-14, 2007, New York City
* 2007 World Congress on Industrial Biotechnology and Bioprocessing
March 21-24, 2007, Orlando, FL
* BIO International Convention
May 6-9, 2007, Boston, MA
SOURCE Biotechnology Industry Organization
 back to top
Related links:
http://www.bio.org/
CONTACT:
Stephanie Fischer of Biotechnology Industry
Organization, +1-202-312-9263
|
